Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of KFD1 Adjuvanted 3R-NC Mucosal Vaccine
NCT06768697Phase 1Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of KFD1 and 3R-NC in coronavirus disease 2019 (COVID-19) (4 arms). Primary endpoint: Safety Tolerance Evaluation Indicators at Day 43. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
KFD13R-NC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06768697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768697.